Biomarkers for Monitoring Dementia Progression
Recruiting now
Conditions studied: Alzheimer Disease
In brief
The variable course of Alzheimer's disease (AD) and the paucity of adequate cures urges to implement new strategies for its early detection and clinical intervention. Studying the etiopathogenesis and pathophysiological mechanisms of AD is a necessary prerequisite for the development of new biomarkers and innovative therapies. Contrarily to anatomical structures, cortical connectivity networks are already deteriorated in early AD and could be a reliable marker of early cognitive decline. Our aim is to characterize the neurophysiological parameters in mild AD, in patients with mild cognitive impairment and in matched healthy subjects to identify discriminating criteria. Concurrently, the study of AD onset and progression in a mouse model, will allow evaluating the causal effect of inflammation on disease progression and to develop a new class of biomimetic anti-inflammatory nanoparticles formulated to have the intrinsic ability to induce brain's activated microglia to an M2 phenotype.
Key facts
- Study ID
- NCT06855368
- Run by
- IRCCS San Raffaele Roma
- People needed
- 300
- Starts
- 2023-05-18
- Expected to finish
- 2025-12-31
- Last updated by the study team
- 2025-03-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- mild AD and patients with mild cognitive impairment (MCI).
You may not qualify if…
- major psychosis, genetic, metabolic and other neurological disorders, acute or chronic non-compensated medical illness
- any medical or drug-related condition affecting cognitive or mood status
- history or current alcohol/illicit drug abuse.
Where it is running
- Azienda Ospedaliero-Universitaria di Sassari — Sassari, Italy (enrolling)
- IRCCS San Raffaele — Roma, Italy
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.